MX383484B - Método para tratar el cáncer. - Google Patents

Método para tratar el cáncer.

Info

Publication number
MX383484B
MX383484B MX2017006089A MX2017006089A MX383484B MX 383484 B MX383484 B MX 383484B MX 2017006089 A MX2017006089 A MX 2017006089A MX 2017006089 A MX2017006089 A MX 2017006089A MX 383484 B MX383484 B MX 383484B
Authority
MX
Mexico
Prior art keywords
treating cancer
inhibitor
ezh2
methods
pharmaceutical compositions
Prior art date
Application number
MX2017006089A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006089A (es
Inventor
Brett Truitt
Futoshi Shikata
Heike Keilhack
Tsukasa Murase
Yuta Suzuki
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Publication of MX2017006089A publication Critical patent/MX2017006089A/es
Publication of MX383484B publication Critical patent/MX383484B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2017006089A 2014-11-17 2015-11-17 Método para tratar el cáncer. MX383484B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (2)

Publication Number Publication Date
MX2017006089A MX2017006089A (es) 2017-12-11
MX383484B true MX383484B (es) 2025-03-11

Family

ID=56014476

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006089A MX383484B (es) 2014-11-17 2015-11-17 Método para tratar el cáncer.
MX2021006734A MX2021006734A (es) 2014-11-17 2017-05-09 Metodo para tratar el cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006734A MX2021006734A (es) 2014-11-17 2017-05-09 Metodo para tratar el cancer.

Country Status (20)

Country Link
US (3) US10786511B2 (https=)
EP (2) EP3220916B1 (https=)
JP (3) JP6829684B2 (https=)
KR (3) KR20240035908A (https=)
CN (2) CN107249591B (https=)
AU (3) AU2015350108B2 (https=)
BR (1) BR112017010166A2 (https=)
DK (1) DK3220916T3 (https=)
EA (1) EA201791095A1 (https=)
ES (1) ES2947819T3 (https=)
FI (1) FI3220916T3 (https=)
HU (1) HUE062159T2 (https=)
IL (4) IL304252B2 (https=)
LT (1) LT3220916T (https=)
MX (2) MX383484B (https=)
PL (1) PL3220916T3 (https=)
PT (1) PT3220916T (https=)
SG (1) SG11201703806XA (https=)
SI (1) SI3220916T1 (https=)
WO (1) WO2016081523A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR20230156450A (ko) 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
BR112016029492A2 (pt) 2014-06-17 2017-10-17 Eisai R&D Man Co Ltd método para tratamento de linfoma não hodgkin
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
AU2016275051A1 (en) 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
JP7125353B2 (ja) 2017-01-19 2022-08-24 第一三共株式会社 Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
WO2008121476A1 (en) * 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
EP2663283B1 (en) * 2011-01-14 2017-05-10 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
ES2951688T3 (es) 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
EP3536314A1 (en) * 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
PT3184523T (pt) 2012-04-13 2019-09-26 Eisai R&D Man Co Ltd Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico
SG10201912111TA (en) * 2012-04-13 2020-02-27 Epizyme Inc Combination therapy for treating cancer
MX2015004721A (es) 2012-10-15 2016-01-25 Epizyme Inc Compuestos de benceno sustituidos.
KR20230156450A (ko) * 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
MA38949A1 (fr) * 2013-10-16 2017-07-31 Eisai R&D Man Co Ltd Forme saline d'hydrochlorure pour inhibition d'ezh2
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
BR112016029492A2 (pt) * 2014-06-17 2017-10-17 Eisai R&D Man Co Ltd método para tratamento de linfoma não hodgkin
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
EA201790845A1 (ru) 2014-10-16 2017-08-31 Эпизайм, Инк. Способ лечения рака
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
AU2016275051A1 (en) * 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
WO2017218953A1 (en) * 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer

Also Published As

Publication number Publication date
EP4272742A1 (en) 2023-11-08
EP3220916B1 (en) 2023-04-19
ES2947819T3 (es) 2023-08-21
PL3220916T3 (pl) 2023-08-14
KR20170103768A (ko) 2017-09-13
JP2023062189A (ja) 2023-05-02
JP2021073241A (ja) 2021-05-13
JP2017537899A (ja) 2017-12-21
FI3220916T3 (fi) 2023-06-19
IL304252B1 (en) 2025-11-01
JP7485810B2 (ja) 2024-05-16
IL296080B1 (en) 2023-08-01
CN107249591B (zh) 2024-01-30
AU2021204706B2 (en) 2023-11-23
IL252182A0 (en) 2017-07-31
IL304252A (en) 2023-09-01
JP6829684B2 (ja) 2021-02-10
EP3220916A1 (en) 2017-09-27
IL304252B2 (en) 2026-03-01
US20210060030A1 (en) 2021-03-04
IL296080A (en) 2022-11-01
IL323396A (en) 2025-11-01
WO2016081523A1 (en) 2016-05-26
PT3220916T (pt) 2023-06-26
CN116650500A (zh) 2023-08-29
AU2015350108A1 (en) 2017-05-25
MX2021006734A (es) 2021-07-02
AU2024201171B2 (en) 2026-01-29
US10786511B2 (en) 2020-09-29
NZ768247A (en) 2024-05-31
AU2021204706A1 (en) 2021-07-29
KR20210156840A (ko) 2021-12-27
AU2015350108B2 (en) 2021-04-08
SI3220916T1 (sl) 2023-09-29
BR112017010166A2 (en) 2018-02-14
NZ731696A (en) 2024-03-22
CN116650500B (zh) 2026-03-06
EP3220916A4 (en) 2018-07-11
US20170360797A1 (en) 2017-12-21
AU2024201171A1 (en) 2024-03-14
EA201791095A1 (ru) 2017-10-31
US20250064822A1 (en) 2025-02-27
US12168014B2 (en) 2024-12-17
IL252182B2 (en) 2023-02-01
LT3220916T (lt) 2023-07-25
CA2967664A1 (en) 2016-05-26
KR102644844B1 (ko) 2024-03-07
MX2017006089A (es) 2017-12-11
IL296080B2 (en) 2023-12-01
CN107249591A (zh) 2017-10-13
KR20240035908A (ko) 2024-03-18
KR102338802B1 (ko) 2021-12-14
DK3220916T3 (da) 2023-06-26
HUE062159T2 (hu) 2023-10-28
SG11201703806XA (en) 2017-06-29
IL252182B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
MX383484B (es) Método para tratar el cáncer.
MX2018002344A (es) Metodo para tratar el cancer.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
MX2016007351A (es) Terapia de combinacion para tratar cancer.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX375706B (es) Compuestos de inhibidor de autotaxina.
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
MX394452B (es) Inhibicion de la actividad de olig2.
ZA201703467B (en) Methods of treating ocular conditions
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2017003463A (es) Inhibidores de histona desmetilasa.
DOP2017000136A (es) Compuestos para tratar el cáncer
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии
AR109858A1 (es) Métodos que usan inhibidores hdac11
EA202091908A3 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1